冠心病患者二级预防用药情况及依从性调查

doi:10.12183/j.scjpm.2023.0297

摘要/Abstract

摘要： 目的调查冠心病患者二级预防用药情况及依从性,为控制冠心病病情提供参考依据。方法以2021年1月至2022年4月新乡医学院第一附属医院诊断为冠心病的患者作为调查对象,调查内容包括患者基本资料、二级预防用药情况及依从性。采用描述性分析方法对冠心病患者二级预防用药情况进行分析,并采用单、多因素分析方法对二级预防用药依从性影响因素进行分析。结果本研究共纳入冠心病患者1 295例进行分析。阿司匹林/硫酸氢氯吡格雷、β-受体阻滞剂、他汀类降脂药、血管紧张素转换酶抑制剂（ACEI）/血管紧张素受体抑制剂（ARB）服用患者分别为964、780、679、482例,分别占74.44%、60.24%、52.44%、37.22%。1 295例冠心病患者服药依从性35.60%（461/1 295）。多因素Logistic回归分析结果显示性别（OR=2.331）、文化程度（OR=1.972）、居住方式（OR=3.009）、病程（OR=1.777）、其他基础疾病（OR=0.647）、每日服药次数（OR=0.583）、药品不良反应（OR=0.219）是冠心病患者服药依从性的影响因素。结论冠心病患者二级预防用药情况及依从性有待改善,性别、文化程度、居住方式、病程、其他基础疾病以及每日服药次数、药品不良反应均会影响到二级预防用药依从性,可针对以上因素明确重点关注人群,加强预防用药管理,提高用药依从性,控制疾病发展。

关键词: 冠心病, 二级预防, 依从性, 影响因素

Abstract: Objective To investigate the secondary prevention medication and compliance of patients with coronary heart disease, and to provide a reference for controlling the condition of coronary heart disease. Methods From January 2021 to April 2022, patients diagnosed with coronary heart disease in the First Affiliated Hospital of Xinxiang Medical College were selected for investigation. The survey content included the basic information of patients, secondary prevention medication, and compliance. Descriptive analysis was used to analyze secondary prevention medication in patients with coronary heart disease, and univariate and multivariate analysis methods were used to analyze the influencing factors of compliance with secondary prevention medication. Results A total of 1 295 patients with coronary heart disease were included in this study for analysis. Of them, 964, 780, 679, and 482 patients were treated with aspirin/Clopidogrel sulfate, β-blockers, statins lipid‐lowering drugs, and angiotensin converting enzyme inhibitors （ACEI）/angiotensin receptor blocker （ARB）, accounting for 74.44%, 60.24%, 52.44%, and 37.22%, respectively. The compliance of 1 295 patients with coronary heart disease was 35.60% （461/1 295）. Multivariate Logistic regression analysis showed that gender （OR=2.331）, education level （OR=1.972）, living style （OR=3.009）, course of disease （OR=1.777）, other underlying diseases （OR=0.647）, daily times of medication （OR=0.583）, adverse drug reactions （OR=0.219） were the influencing factors for medication compliance in patients with coronary heart disease. Conclusions The status and compliance of secondary prevention medication in patients with coronary heart disease need to be improved. Gender, education level, living style, course of disease, other underlying diseases, daily times of medication, and adverse drug reactions can all affect the compliance of secondary prevention medication. It is recommended to focus on the above factors, strengthen the management of prevention medication, and promote the improvement of medication compliance, so as to control the development of disease.

Key words: Coronary heart disease, Secondary prevention, Compliance, Influencing factor

中图分类号:

R541.4

冯楠, 张怡, 段学锋, 石砚秀. 冠心病患者二级预防用药情况及依从性调查[J]. 华南预防医学, 2023, 49(3): 297-300.

FENG Nan, ZHANG Yi, DUAN Xuefeng, SHI Yanxiu. Investigation of secondary prevention medication and compliance in patients with coronary heart disease[J]. South China Journal of Preventive Medicine, 2023, 49(3): 297-300.

参考文献

[1] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2] 中华医学会心血管病学分会,中国康复医学会心血管病专业委员会,中国老年学学会心脑血管病专业委员会.冠心病康复与二级预防中国专家共识[J].中华心血管病杂志,2013,41(4):267-275.
[3] 朱志鸿,杨阳,王云锋,等.中国华中地区冠心病和缺血性脑卒中二级预防抗血小板与他汀治疗现况调查[J].临床心血管病杂志,2022,38(2):101-106.
[4] 龚春梅,袁冰,华征.冠心病患者二级预防用药依从性现状及影响因素分析[J].华南预防医学,2022,48(10):1260-1263.
[5] 中国心血管病预防指南(2017)写作组,中华心血管病杂志编辑委员会.中国心血管病预防指南(2017)[J].中华心血管病杂志,2018,46(1):10-25.
[6] 刘忠凤.冠心病患者二级预防用药依从性的影响因素分析[J].中国社区医师,2019,35(29):43,45.
[7] 韩立霞. 冠心病患者的二级预防用药依从性分析及其相关影响因素[J].中国卫生产业,2016,13(10):175-177.
[8] Lamblin N, Ninni S, Tricot O, et al.Secondary prevention and outcomes in outpatients with coronary artery disease, atrial fibrillation or heart failure: A focus on disease overlap[J].Open Heart,2020,7(1):e001165.
[9] Timmis A, Townsend N, Gale CP, et al.European society of cardiology: Cardiovascular disease statistics 2019[J].Eur Heart J,2020,41(1):12-85.
[10] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.稳定性冠心病基层诊疗指南(2020年)[J].中华全科医师杂志,2021,20(3):265-273.
[11] Lindahl B, Baron T, Erlinge D, et al.Medical therapy for secondary prevention and long‐term outcome in patients with myocardial infarction with nonobstructive coronary artery disease[J]. Circulation,2017,135(16):1481-1489.
[12] 谷云飞,刘彤.2019ESC慢性冠脉综合征指南解读[J].中国循证心血管医学杂志,2020,12(4):388-389.
[13] Alexander Y, Osto E, Schmidt‐Trucksäss A, et al. Endothelial function in cardiovascular medicine:A consensus paper of the European Society of Cardiology Working Groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis[J].Cardiovasc Res,2021,117(1):29-42.
[14] 应用β肾上腺素能受体阻滞剂规范治疗冠心病中国专家共识组.应用β肾上腺素能受体阻滞剂规范治疗冠心病的中国专家共识[J].中国循环杂志,2020,35(2):108-123.
[15] 李秀丽,赵芳,石美丽,等.不同剂量瑞舒伐他汀对CHD并T2DM血脂、Hcy及血粘度的影响[J].分子诊断与治疗杂志,2022,14(11):1862-1866.
[16] 乔岩,王悦,李松南,等.血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂对冠心病合并非瓣膜性心房颤动患者临床结局的影响[J].中国医药,2021,16(12):1769-1773.
[17] 袁艳华,周红漫,李宏才,等.商丘地区冠心病患者健康饮食行为依从性调查及影响因素分析[J].华南预防医学,2022,48(12):1460-1463,1469.
[18] 刘小伟,王江挺,杜常青,等.老年冠心病患者二级预防用药依从性及其相关因素分析[J].心电与循环,2020,39(5):438-441.
[19] 王艳岭,张锐.冠心病患者服药依从性研究进展[J].中国卫生产业,2016,13(1):169-171.
[20] 褚娜,刘晓明.提高冠心病患者服药依从性的研究进展[J].世界最新医学信息文摘,2021,21(34):70-72.
[21] 张利娜,史历.慢性病管理模式下社区干预对冠心病患者服药依从性和自我效能的影响[J].中国初级卫生保健,2020,34(12):23-25.